| Guidance for Transitioning Among Anticoagulants | AACN Advanced Critical Care | 2019 |
| Thromboprophylaxis in Orthopedic Surgery | | 2016 |
| Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study | Journal of Thrombosis and Thrombolysis | 2021 |
| Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study | British Journal of Clinical Pharmacology | 2020 |
| Drug-Drug Interactions with Direct Oral Anticoagulants | Clinical Pharmacokinetics | 2020 |
| Cardiovascular Risk Management and Hepatitis C: Combining Drugs | Clinical Pharmacokinetics | 2019 |
| A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4 | Clinical Pharmacokinetics | 2019 |
| Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants | Journal of Thrombosis and Haemostasis | 2019 |
| How Does "Regulatory Practice" Create Discrepancies in Drug Label Information Between Asian and Western Countries? Different Label Information for Direct Oral Anticoagulants Approved in the United States, Europe, Korea, and Japan | Therapeutic Innovation and Regulatory Science | 2019 |
| Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report | Chest | 2018 |
| Oral Anticoagulation in Patients With Liver Disease | Journal of the American College of Cardiology | 2018 |
| Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation | Thrombosis Journal | 2018 |
| Management of Dabigatran-associated bleeding in two elderly patients with acute renal failure | Annals of Hematology | 2018 |
| Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients | Journal of Thrombosis and Thrombolysis | 2018 |
| Hepatotoxicity of New Oral Anticoagulants | Rational Pharmacotherapy in Cardiology | 2018 |
| Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice | British Journal of Clinical Pharmacology | 2018 |
| Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians | Journal of Thrombosis and Haemostasis | 2018 |
| Direct-acting oral anticoagulant drug level monitoring in clinical patient management | Journal of Thrombosis and Thrombolysis | 2018 |
| Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting | Oncologist | 2018 |
| Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban | Current Medical Research and Opinion | 2018 |
| Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence? | Research and Practice in Thrombosis and Haemostasis | 2018 |
| Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury | Journal of the American College of Cardiology | 2018 |
| Haematological factors in the management of adult epistaxis: systematic review | Journal of Laryngology and Otology | 2017 |
| Direct oral anticoagulant considerations in solid organ transplantation: A review | Clinical Transplantation | 2017 |
| Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis | British Journal of Clinical Pharmacology | 2017 |
| Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs | European Journal of Clinical Pharmacology | 2017 |
| Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records | European Journal of Clinical Pharmacology | 2017 |
| Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views | Hemodialysis International | 2017 |
| Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA) | European Heart Journal - Cardiovascular Pharmacotherapy | 2017 |
| Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation | Expert Opinion on Pharmacotherapy | 2017 |
| Medication errors involving anticoagulants: Data from the Danish patient safety database | Pharmacology Research and Perspectives | 2017 |
| Perioperative management of patients on direct oral anticoagulants | Thrombosis Journal | 2017 |
| Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin | Journal of Thrombosis and Haemostasis | 2017 |
| Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment | International Journal of Hematology | 2017 |
| Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation | Journal of Thrombosis and Thrombolysis | 2017 |
| Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants | Critical Care | 2017 |
| Novel oral anticoagulants and the 73rd anniversary of historical warfarin | Journal of the Saudi Heart Association | 2016 |
| Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome | Rheumatology | 2016 |
| Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants | Cardiovascular Drugs and Therapy | 2016 |
| Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting | Thrombosis Journal | 2016 |
| Drug Treatment of Venous Thromboembolism in the Elderly | Drugs and Aging | 2016 |
| The Effect of Cardiopulmonary Bypass on Dabigatran Levels | Journal of Cardiothoracic and Vascular Anesthesia | 2016 |
| Managing novel orally administered anticoagulants in patients undergoing urogynaecological surgery | International Urogynecology Journal | 2016 |
| Glomerular filtration rate assessed by using creatinine and cystatin in patients treated with dabigatran | Rivista Italiana Della Medicina Di Laboratorio | 2016 |
| Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE | Thrombosis and Haemostasis | 2016 |
| The use of novel oral anticoagulants in cancer patients with venous thromboembolism | Seminars in Oncology | 2016 |
| Drug-drug interactions of non-vitamin K oral anticoagulants | Expert Opinion on Drug Metabolism and Toxicology | 2016 |
| Use of direct oral anticoagulants with regional anesthesia in orthopedic patients | Journal of Clinical Anesthesia | 2016 |
| Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation | European Heart Journal Supplements | 2016 |
| Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation | European Heart Journal Supplements | 2016 |
| A Case of Fatal Bleeding Following Emergency Surgery on an Ascending Aorta Intramural Hematoma in a Patient Taking Dabigatran | Journal of Cardiothoracic and Vascular Anesthesia | 2016 |
| Clinical considerations on the posology of direct oral anticoagulants | Revista Clinica Espanola | 2016 |
| Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin | Pharmacotherapy | 2016 |
| Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis-A simulation analysis | Journal of Clinical Pharmacology | 2016 |
| Spotlight on real-world evidence for the treatment of DVT: XALIA | Thrombosis and Haemostasis | 2016 |
| Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials | Thrombosis and Haemostasis | 2016 |
| Dabigatran approaching the realm of heparin-induced thrombocytopenia | Blood Research | 2016 |
| Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation | Thrombosis and Haemostasis | 2016 |
| Bleeding events with dabigatran or warfarin in patients with venous thromboembolism | Thrombosis and Haemostasis | 2016 |
| Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism | Drugs | 2015 |
| Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation | Revista Espanola De Cardiologia (English Ed ) | 2015 |
| Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study | Circulation | 2015 |
| Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities | Drugs | 2015 |
| Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients | Journal of Thrombosis and Thrombolysis | 2015 |
| Effective practical management of patients with atrial fibrillation when using new oral anticoagulants | Annals of Medicine | 2015 |
| Reversal of antithrombotic treatment in intracranial hemorrhage--A review of current strategies and guidelines | Neurologia I Neurochirurgia Polska | 2015 |
| Comparación de las ecuaciones de filtrado glomerular estimado para determinar la posología de los nuevos anticoagulantes orales para pacientes con fibrilación auricular | Revista Espanola De Cardiologia | 2015 |
| Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system | British Journal of Clinical Pharmacology | 2015 |
| Real-world variability in dabigatran levels in patients with atrial fibrillation | Journal of Thrombosis and Haemostasis | 2015 |
| Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays | Thrombosis and Haemostasis | 2015 |
| Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism | Thrombosis and Haemostasis | 2015 |
| Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey | Thrombosis and Haemostasis | 2015 |
| Real-world variability in dabigatran levels in patients with atrial fibrillation: comment | Journal of Thrombosis and Haemostasis | 2015 |
| Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives | European Journal of Haematology | 2015 |
| Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach | BMC Cardiovascular Disorders | 2015 |
| Dabigatran and bleeding risk: the importance of a correct prescription | Journal of Emergency Medicine | 2014 |
| Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions | Journal of Clinical Pharmacy and Therapeutics | 2014 |
| Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain | Pharmacoeconomics | 2014 |
| Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C | Drugs in R and D | 2014 |
| Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence | Drugs | 2014 |
| Novel oral anticoagulants for stroke prevention in the geriatric population | American Journal of Cardiovascular Drugs | 2014 |
| Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis | Heart | 2014 |
| Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism | Drugs | 2014 |
| A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban | Journal of Thrombosis and Thrombolysis | 2014 |
| Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban | Clinical Pharmacokinetics | 2014 |
| Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials | Seminars in Hematology | 2014 |
| The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome | Current Medical Research and Opinion | 2014 |
| Treatment options for venous thromboembolism: lessons learnt from clinical trials | Thrombosis Journal | 2014 |
| An explanation of recommendation differences: illustrations from recent atrial fibrillation guidelines | PACE - Pacing and Clinical Electrophysiology | 2014 |
| Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation | Clinical Cardiology | 2014 |
| Direct oral anticoagulants: new drugs and new concepts | JACC: Cardiovascular Interventions | 2014 |
| Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population | The Consultant Pharmacist | 2014 |
| Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation | Thrombosis and Haemostasis | 2014 |
| Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban | Thrombosis and Haemostasis | 2013 |
| Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate | Thrombosis and Haemostasis | 2013 |
| The pharmacology and therapeutic use of dabigatran etexilate | Journal of Clinical Pharmacology | 2013 |
| Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation | Drugs | 2013 |
| Pharmacology of the new target-specific oral anticoagulants | Journal of Thrombosis and Thrombolysis | 2013 |
| Novel oral anticoagulants: clinical pharmacology, indications and practical considerations | European Journal of Clinical Pharmacology | 2013 |
| Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis | Journal of Thrombosis and Haemostasis | 2013 |
